Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 301–400 of 1,000
Immune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2018) · Cancer · doi:10.1002/cncr.31105 · Cited by 121
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
Eschweiler, S., Clarke, J. D., Ramírez-Suástegui, C., Panwar, B., Madrigal, A., Chee, S., Karydis, I., Woo, E. B. C., Alzetani, A., Elsheikh, S. E., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00958-6 · Cited by 130
CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells
Kim, M., Borcherding, N. C., Ahmed, K. K., Voigt, A. P., Vishwakarma, A., Kolb, R. H., Kluz, P., Pandey, G., De, U., Drashansky, T. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26091-4 · Cited by 146
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Pitt, J. M., Vétizou, M., Waldschmitt, N., Kroemer, G., Chamaillard, M., Boneca, I. G., & Zitvogel, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0448 · Cited by 117
“Tregs express high surface levels of CTLA-4; thus, anti-CTLA-4 mAb therapy acts also to deplete these cells from the tumor microenvironment, resulting in a subsequent release in suppression of antitumoral CTL activity (12).”
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 127
CD8+ T cell-based cancer immunotherapy
Chen, Y., Yu, D., Qian, H., Shi, Y., & Tao, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05134-6 · Cited by 132
“Canonically, the more severely depleted T cells are, the more inhibitory receptors are expressed on the cell surface, reducing the sensitivity to antigenic stimulation [82].”
BackgroundKnorr, D. A., Dahan, R., & Ravetch, J. V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810566115 · Cited by 120
Self-citationBelmontes, B., Sawant, D. V., Zhong, W., Tan, H. L. E., Kaul, A. M., Aeffner, F., O’Brien, S. A., Chun, M. G. H., Noubade, R., Eng, J. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1524 · Cited by 126
“To further investigate potential contributions of Treg cells to TCE-mediated efficacy, we evaluated the effect of anti–CTLA-4 therapy on various BiTE combinations in the KPC M5 model, using a CTLA-4 antibody previously shown to efficiently deplete intratumoral Treg cells (49, 50).”
MethodChemotherapy and tumor microenvironment of pancreatic cancer
Liu, Q., Liao, Q., & Zhao, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0437-3 · Cited by 120
“In murine models, depletion of Treg cells by macrophage-mediated ADCC was an essential component of the effects of anti-CTLA-4 [188].”
BackgroundJing, W., Gershan, J. A., Weber, J. J., Tlomak, D., McOlash, L., Sabatos-Peyton, C. A., & Johnson, B. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0043-z · Cited by 130
“Notably, CTLA4 blockade results in increased ratios of effector CD8 T cells to regulatory T cells in tumors, possibly due to higher levels of CTLA4 expression by regulatory T cells [4].”
BackgroundKvarnhammar, A. M., Veitonmäki, N., Hägerbrand, K., Dahlman, A., Smith, K. E., Fritzell, S., von Schantz, L., Thagesson, M., Werchau, D., Smedenfors, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0570-8 · Cited by 115
Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy
Escors, D. (2014) · New Journal of Science · doi:10.1155/2014/734515 · Cited by 112
“So, instead of blocking CTLA4 activities on Treg cells, it seems that this antibody physically removes Tregs via macrophages [284].”
BackgroundImmune evasion in acute myeloid leukemia: current concepts and future directions
Teague, R. M., & Kline, J. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-13 · Cited by 137
“Blockade of CTLA-4 enhances tumor immunity in animal models of cancer, which is thought to rely on the enhancement of effector T cell activity, and the inhibition or deletion of regulatory T cells [26-28].”
New Immunotherapy Strategies in Breast Cancer
Yu, L., Tang, J., Zhang, C., Zeng, W., Yan, H., Li, M.-P., & Chen, X. (2017) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph14010068 · Cited by 126
Kumar, P., Saini, S., & Prabhakar, B. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.006 · Cited by 117
Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells
Kleinovink, J. W., Fransen, M. F., Löwik, C. W. G. M., & OSSENDORP, F. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0055 · Cited by 119
“CTLA-4 blockade specifically depletes tumor-infiltrating regulatory T cells in several tumor models, including MC38 and CT26, favoring the subsequent expansion of intratumoral effector CD8þ T cells (23, 24).”
BackgroundTargeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 120
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy
Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2021) · European Journal of Immunology · doi:10.1002/eji.202048992 · Cited by 115
Onda, M., Kobayashi, K., & Pastan, I. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820388116 · Cited by 124
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Abdoli Shadbad, M., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 107
“Another suggested mechanism by CTLA-4 mAbs is the Treg exhaustion in the tumor microenvironment (TME) [45,46].”
BackgroundInfluentialImmunotherapy for cancer treatment during pregnancy
Borgers, J. S. W., Heimovaara, J. H., Cardonick, E., Dierickx, D., Lambertini, M., Haanen, J. B. A. G., & Amant, F. C. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00525-8 · Cited by 128
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2015) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
Advances in Therapeutic Cancer Vaccines
Wong, K. K. W., Li, A. W., Mooney, D. J., & Dranoff, G. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.001 · Cited by 127
Li, F., & Ravetch, J. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319502110 · Cited by 110
“Simpson TR, et al. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.”
BackgroundSelf-citationHarnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 120
“Recent studies have shown that the primary mechanism of action of anti-CTLA-4 in solid tumour patients may actually be the depletion of intra-tumoral Tregs rather than direct action on effector cytotoxic T cells [220].”
Tang, F., Du, X., Liu, M., Zheng, P., & Liu, Y. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0229-z · Cited by 114
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 122
“5- to two-fold increase in the proliferation of T cells, a six-fold increase in the production of interleukin-2 [9,10] and the depletion of T regulatory lymphocytes in the tumor microenvironment through a macrophage-dependent process [10,11].”
BackgroundLo, B. C., Kryczek, I., Yu, J., Vatan, L., Caruso, R., Matsumoto, M., Sato, Y., Shaw, M. H., Inohara, N., Xie, Y., et al. (2024) · Science · doi:10.1126/science.adh8342 · Cited by 118
Crocenzi, T. S., Cottam, B., Newell, P., Wolf, R., Hansen, P., Hammill, C. W., Solhjem, M. C., To, Y.-Y., Greathouse, A., Tormoen, G. W., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0149-6 · Cited by 118
“In addition, therapy using anti-CTLA4, which depletes T regulatory cells in the tumor as a necessary mechanism of action [36, 37], synergizes with hypofractionated radiation therapy in mouse models [38, 39] and a number of clinical anecdotes have been reported where anti-CTLA4 plus hypofractionated…”
BackgroundShi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P. (2016) · Nature Communications · doi:10.1038/ncomms12335 · Cited by 111
Self-citationCytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
Yu, H., Yang, J., Jiao, S., Li, Y., Zhang, W., & Wang, J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1696-2 · Cited by 112
“Anti-CTLA-4 blockade also depleted intratumoral CTLA-4+ Treg cells by macrophages via ADCC in recent reports [17–19], which implies that CTLA-4 blockade can activate anti-tumor immunity in the presence of enough tumor-infiltrating lymphocytes (TILs).”
BackgroundRoles for Innate Immunity in Combination Immunotherapies
Moynihan, K. D., & Irvine, D. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1340 · Cited by 108
Bartkowiak, T., Jaiswal, A. R., Ager, C. R., Chin, R., Chen, C.-H., Budhani, P., Ai, M., Reilley, M. J., Sebastian, M. M., Hong, D. S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1847 · Cited by 105
Raza, A., Merhi, M., Inchakalody, V. P., Krishnankutty, R., Relecom, A., Shahab Uddin, M. S., & Dermime, S. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02306-y · Cited by 116
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 126
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 105
“Many promising emerging immunotherapeutic modalities are based on targeting these molecules in the TME ( Fig.”
BackgroundInfluentialImmuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 114
Singh, M., Vianden, C., Cantwell, M. J., Dai, Z., Xiao, Z., Sharma, M., Khong, H., Jaiswal, A. R., Fa’ak, F., Hailemichael, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01572-7 · Cited by 112
Single-cell genomic approaches for developing the next generation of immunotherapies
Yofe, I., Dahan, R., & Amit, I. (2020) · Nature Medicine · doi:10.1038/s41591-019-0736-4 · Cited by 114
Extricating human tumour immune alterations from tissue inflammation
Mair, F., Erickson, J. R., Frutoso, M., Konecny, A., Greene, E., Voillet, V., Maurice, N. J., Rongvaux, A., Dixon, D. R., Barber, B. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04718-w · Cited by 115
Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
Yue, T., Li, J., Zhu, J., Zuo, S., Wang, X., Liu, Y., Liu, J., Liu, X., Wang, P., & Chen, S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1837 · Cited by 112
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
Crittenden, M. R., Zebertavage, L., Kramer, G. F., Bambina, S., Friedman, D. J., Troesch, V., Blair, T. C., Baird, J. R., Alice, A. F., & Gough, M. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25482-w · Cited by 110
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Yoshida, K., Okamoto, M., Sasaki, J., Kuroda, C., Ishida, H., Ueda, K., Ideta, H., Kamanaka, T., Sobajima, A., Takizawa, T., et al. (2020) · BMC Cancer · doi:10.1186/s12885-019-6499-y · Cited by 112
Waight, J. D., Chand, D., Dietrich, S., Gombos, R., Horn, T., Gonzalez, A. M., Manrique, M., Swiech, L., Morin, B., Brittsan, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.005 · Cited by 104
Mechanisms of human FoxP3+ Treg cell development and function in health and disease
Attias, M., Al-Aubodah, T.-A., & Piccirillo, C. A. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13290 · Cited by 114
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 113
Nimmerjahn, F., Vidarsson, G., & Cragg, M. S. (2023) · Nature Immunology · doi:10.1038/s41590-023-01544-8 · Cited by 112
Combining radiotherapy with immunotherapy: the past, the present and the future
Limbergen, E. J. V., Ruysscher, D. D., Pimentel, V. O., Marcus, D., Berbée, M., Hoeben, A., Rekers, N. H., Theys, J., Yaromina, A., Dubois, L. J., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170157 · Cited by 107
“The authors proposed that OX-40 would function by boosting antigen-specific T-cell numbers,(80,81) whereas anti-CTLA-4 would rather function as a downregulator of regulatory T cells.(80,82) Therefore, OX40 inhibition would be most beneficial just following radiation-induced antigen release.”
BackgroundRegulators of CD8+ T cell exhaustion
Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 116
“CTLA4 inhibition promotes the expansion of ICOS + T helper 1 (T H 1)-like effector CD4 + T cells while reducing regulatory T (T reg ) cells within the TME 62,64 .”
Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 120
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.002 · Cited by 118
“Treatment with an anti-CTLA-4 antibody in a tumor model showed activation of effector T cell function, promoted Treg depletion, and enhanced the antitumor immune response and tumor regression [66,67].”
BackgroundRevilla, S. A., Kranenburg, O., & Coffer, P. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903564 · Cited by 116
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Babamohamadi, M., Mohammadi, N., Faryadi, E., Haddadi, M., Merati, A., Ghobadinezhad, F., Amirian, R., Izadi, Z., & Hadjati, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06391-x · Cited by 107
Burbach, B. J., O’Flanagan, S. D., Shao, Q., Young, K. M., Slaughter, J. R., Rollins, M. R., Street, T. J. L., Granger, V., Beura, L. K., Azarin, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24132-6 · Cited by 110
Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe, A. E., & Vignali, D. A. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0066 · Cited by 102
“Subsequent studies suggested that CTLA-4 blockade also led to increased Teffs in both the tumor and periphery, highlighting a role for both Tregs and Teff in patient response (25).”
BackgroundSato, Y., Fu, Y., Liu, H., Lee, M. Y., & Shaw, M. H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08974-3 · Cited by 109
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R., Schulick, R., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 97
“In addition to inhibiting the CTLA-4 inhibitory signal, recent work has su gested that selectively depleting regulatory T (Treg) cells at tumor sites, which happen to express the highest level of surface CTLA-4, is critical for CTLA-4 mAb-m diated antitumor effect [18].”
BackgroundSoluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Khan, M. S. I., Arooj, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651634 · Cited by 106
Fcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
“Although tiragolumab was initially developed as an immune checkpoint inhibitor, its hIgG1 backbone raises questions regarding its potential depleting activity against TIGIT + T eff cells and T reg cells within the TME.”
InfluentialSelf-citationBartkowiak, T., Singh, S., Yang, G., Sierra, G., Haria, D., Ai, M., Allison, J. P., Sastry, K. J., & Curran, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1514418112 · Cited by 106
Self-citationAlissafi, T., Hatzioannou, A., Legaki, A. I., Varveri, A., & Verginis, P. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102310 · Cited by 106
Mechanisms of immune checkpoint inhibitor-mediated liver injury
Shojaie, L., Ali, M., Iorga, A., & Dara, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.003 · Cited by 98
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions
Osorio, J. C., Smith, P. T., Knorr, D. A., & Ravetch, J. V. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.007 · Cited by 101
Self-citationJochéms, C., Tucker, J. A., Tsang, K.-Y., Madan, R. A., Dahut, W. L., Liewehr, D. J., Steinberg, S. M., Gulley, J. L., & Schlom, J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1524-0 · Cited by 100
“Regimens that decrease the numbers and/or activity of the Treg population have shown promising results, and one previous study showed that the efficacy of anti-CTLA-4 treatment against melanoma was mediated by Fc-dependent depletion of tumor-infiltrating Tregs [40].”
InfluentialImmunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 106
“This diversity made researchers to explore more regarding the role of tumor microenvironment in immunotherapy, resulted in understanding the function of intratumoral FcγR+ macrophages in depleting Treg cells [23].”
BackgroundNegative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 101
Self-citationMarchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A. L., & Rommelaere, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01848 · Cited by 101
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
Targeting regulatory T cells in anti‐PD‐1/PD‐L1 cancer immunotherapy
Жулай, Г. А., & Олейник, Е. К. (2022) · Scandinavian Journal of Immunology · doi:10.1111/sji.13129 · Cited by 100
Vazquez-Lombardi, R., Loetsch, C., Zinkl, D., Jackson, J., Schofield, P., Deenick, E. K., King, C., Phan, T. G., Webster, K. E., Sprent, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15373 · Cited by 95
“In particular, Fc g R-mediated Treg depletion has been recently described as a critical component in the antitumour activity of antibodies targeting CTLA-4, OX40 and GITR 45–47 .”
Albu, D. I., Wang, Z., Huang, K.-C., Wu, J., Twine, N., Leacu, S., Ingersoll, C., Parent, L., Lee, W., Liu, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338239 · Cited by 92
Ahern, E. S., Harjunpää, H., O’Donnell, J. S., Allen, S. M., Dougall, W. C., Teng, M. W. L., & Smyth, M. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431088 · Cited by 98
“Although in mice, full efficacy of anti-CTLA4 relies on FcR-mediated depletion of Tregs, the precise mechanism of action of the FDA-approved human IgG1 antibody, ipilimumab, remains controversial.(20,24,25)”
BackgroundNew Strategies in Bladder Cancer: A Second Coming for Immunotherapy
Ghasemzadeh, A., Bivalacqua, T. J., Hahn, N. M., & Drake, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1135 · Cited by 104
“However, one potential explanation is that CTLA-4 is highly expressed on regulatory T cells (39), which play an important role in maintaining peripheral tolerance (40, 41) and which are present in abundance in multiple tissue types including the skin, gut, liver, and others.”
BackgroundHelmin, K. A., Morales-Nebreda, L., Acosta, M. A. T., Anekalla, K. R., Chen, S.-Y., Abdala-Valencia, H., Politanska, Y., Cheresh, P., Akbarpour, M., Steinert, E. M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137712 · Cited by 91
Regulatory T Cells in Autoimmunity and Cancer: A Duplicitous Lifestyle
Hatzioannou, A., Boumpas, A., Papadopoulou, M., Papafragkos, I., Varveri, A., Alissafi, T., & Verginis, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731947 · Cited by 106
Clavijo, P. E., Moore, E. C., Chen, J., Davis, R. J., Friedman, J., Kim, Y., Van Waes, C., Chen, Z., & Allen, C. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18437 · Cited by 91
“FoxP3+ regulatory CD4+ T-lymphocytes (Tregs) were stained using the Mouse Regulatory T Cell Staining Kit #1 (eBioscience) per manufacturer protocol.”
InfluentialTargeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 82
“Notably, TAMs express the CTLA‐4 ligands B7‐1 and B7‐2, and play an important role in the T‐cell‐mediated immune response (Simpson et al., 2013).”
BackgroundDeVito, N. C., Sturdivant, M. S., Thievanthiran, B., Xiao, C., Plebanek, M. P., Salama, A. K. S., Beasley, G. M., Holtzhausen, A., Novotny‐Diermayr, V., Strickler, J. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109071 · Cited by 93
Harnessing the biology of regulatory T cells to treat disease
Wardell, C. M., Boardman, D. A., & Levings, M. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01089-x · Cited by 100
“As discussed above, T reg cells express constitutively high levels of CTLA4 so it is not surprising that anti-CTLA4 antibodies inhibit them 247,248 .”
Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
Ilieva, K. M., Correa, I., Josephs, D. H., Karagiannis, P., Egbuniwe, I. U., Cafferkey, M. J., Spicer, J. F., Harries, M., Nestle, F. O., Lacy, K. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0290 · Cited by 87
“Another study confirmed that a BRAF inhibitor selective for BRAFV600E, BRAFV600K, and BRAFV600G did not affect cancer patients’ immunity in relation to a number of clinical parameters, such as serumcytokine levels, peripheral blood mononuclear cell counts and frequencies of different leukocyte subsets (B cells, T cell…”
BackgroundInfluentialKersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 89
“org in the TME by inactivating Tregs in an Fc-dependent manner resulting in a favorable shift in the effector T cell/Treg ratio (38).”
BackgroundThe role of microbiota in cancer therapy
Perez-Chanona, E., & Trinchieri, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.01.003 · Cited by 90
Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
Richman, L. P., & Vonderheide, R. H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0152 · Cited by 91
The Immunobiology of Kidney Cancer
Drake, C. G., & Stein, M. N. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2648 · Cited by 104
The Crosstalk between Microbiome and Immune Response in Gastric Cancer
Nasr, R., Shamseddine, A. I., Mukherji, D., Nassar, F. J., & Temraz, S. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186586 · Cited by 99
“By inhibiting the interaction between CTLA-4 and B7 on antigen-presenting cells through the use of an antiCTLA-4 antibody (Figure 2), T cell activation and proliferation is promoted, along with a decrease in immunosuppressive Treg cells among TILs [72].”
BackgroundThe Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
“The ratio of Teffs to Tregs was shown to be related to the responses to ICIs in mouse models, in that incapacity of either increasing Teffs or decreasing Tregs may cause resistance to immunotherapy (188, 189).”
BackgroundThe Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer
Nair, S. S., Weil, R., Dovey, Z. S., Davis, A., & Tewari, A. K. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.10.005 · Cited by 98
Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer
Bakema, J. E., & van Egmond, M. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_17 · Cited by 99
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed Central · Cited by 112
Nederlof, I., Isaeva, O. I., de Graaf, M., Gielen, R., Bakker, N. A. M., Rolfes, A. L., Garner, H., Boeckx, B., Traets, J. J. H., Mandjes, I. A. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03249-3 · Cited by 94
“A growing body of literature analyzing anti-CTLA4 using in vivo models indicates that anti-CTLA4 can deplete T reg cells 48 ; however, whether anti-CTLA4 can deplete T reg cells in human tumors remains a matter of debate 49 .”
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A., Tötterman, T. H., & Mangsbo, S. M. (2014) · OncoImmunology · doi:10.4161/onci.27614 · Cited by 97
Tremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 97
“There was a better survival of patients with CD4 + ICOS + T-cells circulating over a value of 54 cells/ μ L and 26 cells/ μ L at days 30 and 26, respectively.”
Ahern, E., Harjunpää, H., Barkauskas, D., Allen, S., Takeda, K., Yagita, H., Wyld, D., Dougall, W. C., Teng, M. W. L., & Smyth, M. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0606 · Cited by 87
“C57BL/6 perforin-deficient (pfp / ), interferon-deficient (IFNg / ), Fc receptor deficient (FcgRIII, FcgRIV, and FceRg), Batf3 transcription factor–deficient (Batf3 / ; ref.”
BackgroundMethodInfluentialSelf-citationTumour islet Foxp3+T-cell infiltration predicts poor outcome in nonsmall cell lung cancer
O'Callaghan, D. S., Rexhepaj, E., Gately, K., Coate, L., Delaney, D., O'Donnell, D. M., Kay, E., O'Connell, F., Gallagher, W. M., & O'Byrne, K. J. (2015) · European Respiratory Journal · doi:10.1183/13993003.00176-2014 · Cited by 81
Adler, B. L., Pezhouh, M. K., Kim, A., Luan, L., Zhu, Q., Gani, F., Yarchoan, M. M., Chen, J., Voltaggio, L., Parian, A. M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12744 · Cited by 87
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
Immunoglobulin isotype knowledge and application to Fc engineering
Brezski, R. J., & Georgiou, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.002 · Cited by 101
Haematological malignancies: at the forefront of immunotherapeutic innovation
Bachireddy, P., Burkhardt, U. E., Rajasagi, M., & Wu, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3907 · Cited by 85
Current status and perspectives in immunotherapy for metastatic melanoma
Marconcini, R., (IMI), F. T. I. M. I., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., Rosa, F. D., Picasso, V., Guardo, L. D., Cimminiello, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23746 · Cited by 90
“Anti-CTLA-4 agents can indeed upregulate PD-L1 expression, potentially enhancing the action of a subsequent PD1/PD-L1 inhibition in tumor microenvironment [19].”
BackgroundTherapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 89
“ecule in the tumor microenvironment [141, 142], while anti-”
Background
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.